A5000204001- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Cancer survivorship and care
- RNA modifications and cancer
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Cancer, Hypoxia, and Metabolism
- Frailty in Older Adults
- Metastasis and carcinoma case studies
- Cancer-related cognitive impairment studies
- Palliative Care and End-of-Life Issues
Hospital Universitario La Paz
2016-2025
Universidad Autónoma de Madrid
2016-2025
Hospital La Paz Institute for Health Research
2014-2025
Instituto de Salud Carlos III
2017-2025
Centro de Investigación Biomédica en Red de Cáncer
2016-2025
Centre for Biomedical Network Research on Rare Diseases
2018-2023
Central University Hospital of Asturias
2023
Hospital Universitario Infanta Sofía
2023
Medical Research Network
2022
Ministry of Economy, Industry and Competitiveness
2017
<h3>Objective</h3> Hypomethylation of LINE-1 elements has emerged as a distinguishing feature in human cancers. Limited evidence indicates that some encode an additional internal antisense promoter, and increased hypomethylation this region may lead to inadvertent activation evolutionarily methylation-silenced downstream genes. However, the significance fundamental epigenetic mechanism colorectal cancer (CRC) not been investigated previously. <h3>Design</h3> We analysed tissue specimens from...
KRAS mutations in colorectal cancer primary tumors predict resistance to anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody therapy patients with metastatic cancer, and thus represent a true indicator of EGFR pathway activation status.KRAS were retrospectively studied using polymerase chain reactions subsequent sequencing codons 12 13 (exon 2) 110 tumors. These studies performed tissue samples from both the tumor their related metastases (93 liver, 84%; 17 lung, 16%). All...
// Ruth Sánchez-Martínez 1 , Silvia Cruz-Gil 1, * Marta Gómez de Cedrón Mónica Álvarez-Fernández 2 Teodoro Vargas Susana Molina Belén García Jesús Herranz 3 Juan Moreno-Rubio 4, 5 Guillermo Reglero Mirna Pérez-Moreno 6 Jaime Feliu 4 Marcos Malumbres Ana Ramírez Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM + CSIC, Madrid, Spain Cell Division Spanish National...
At the time of diagnosis, 20% patients with colorectal cancer present metastasis. Among individuals primary lesions, 50% them will develop distant tumours time. Therefore, early diagnosis and prediction aggressiveness is crucial for therapy design disease prognosis. Tumoral cells must undergo significant changes in energy metabolism to meet increased structural energetic demands cell proliferation, metabolic alterations are considered be a hallmark cancer. Here, we ATP-binding cassette...
Pancreatic ductal adenocarcinoma (PDAC) is largely unresponsive to checkpoint inhibitors. Blockade of the CXCR4/CXCL12 axis increases intratumoral trafficking activated T cells while restraining immunosuppressive elements. This study evaluates dual blockade CXCR4 and PD1 with chemotherapy in PDAC.Multicenter, single-arm, phase II evaluate safety efficacy motixafortide pembrolizumab combined patients de novo metastatic PDAC disease progression on front-line gemcitabine-based therapy...
•This ESMO Clinical Practice Guideline provides key recommendations for using prognostic estimates in advanced cancer.•The guideline covers patients with cancer and an expected survival of months or less.•An algorithm use clinical predictions, factors multivariable risk prediction models is presented.•The author group encompasses a multidisciplinary experts from different institutions Europe, USA Asia.•Recommendations are based on available scientific data the authors' collective expert opinion.
Background/Objectives: Dysgeusia contributes to malnutrition and worsens the quality of life patients with cancer. Despite different strategies, there is no effective treatment for suffering from taste disorders provided by pharmaceutical industry. Therefore, we developed a novel strategy reducing side effects in cancer providing food supplement taste-modifying glycoprotein miraculin, which approved European Union, as an adjuvant medical–nutritional therapy. Methods: A pilot randomized,...
PURPOSE EXONERATE (EXOsome and cell-free micro-RNAs of anti-EGFR ResistAnce) was an open-label, biomarker interventional study designed to develop, test, validate a liquid biopsy predictive progression-free survival (PFS), overall (OS), objective response rate (ORR) for first-line EGFR inhibitors in metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Patients with newly diagnosed RAS-WT, chemotherapy-naïve mCRC, both right- left-sided, were enrolled 2-nationwide trials receive...
To determine the tolerability of capecitabine in elderly patients with advanced colorectal cancer (CRC).Fifty-one CRC who were >/= 70 years and considered ineligible for combination chemotherapy received oral 1,250 mg/m(2) twice daily on days 1 to 14 every 3 weeks. Patients a creatinine clearance 30 50 mL/min dose 950 daily.A total 248 cycles administered (median, five cycles; range, one eight cycles). The overall response rate was 24% (95% CI, 15% 41%), including two complete responses (CR;...
The purpose of this phase II trial was to determine the efficacy and safety XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in elderly patients with metastatic colorectal cancer (MCRC). A total 50 MCRC aged ⩾70 years received oxaliplatin 130 mg m−2 on day 1 followed by oral capecitabine 1000 twice daily days 1–14 every 3 weeks. Patients creatinine clearance 30–50 ml min−1 a reduced dose (750 daily). By intent-to-treat analysis, overall response rate 36% (95% CI, 28–49%), three...
BackgroundDetermining life expectancy in terminally ill cancer patients is a difficult task. We aimed to develop and validate nomogram predict the length of survival with terminal disease.
This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions accuracy with which physicians perceive CINV.Chemotherapy-naive patients receiving MEC between April 2012 May 2013 were included. Patients completed a diary intensity number episodes. Complete response complete protection assessed as secondary endpoints.Of 261 included, 240 evaluated. Median age was 64 years, 44.2 % female 11.2 aged less...
// Teodoro Vargas 1 , Juan Moreno-Rubio 2, 3 Jesús Herranz 4 Paloma Cejas 5 Susana Molina Margarita González-Vallinas Marta Mendiola 2 Emilio Burgos 5, 6 Cristina Aguayo 7 Ana B. Custodio Isidro Machado 8 David Ramos 9 Meritxell Gironella 10 Isabel Espinosa-Salinas Ricardo 11 Roberto Martín-Hernández Alberto Risueño 12 Javier De Las Rivas Guillermo Reglero Yaya 13 Carlos Fernández-Martos Jorge Aparicio 14 Joan Maurel 15 Jaime Feliu Ramírez de Molecular Oncology, IMDEA-Food Institute, CEI...
Abstract Background. The need for preoperative chemoradiation or short-course radiation in all T3 rectal tumors is a controversial issue. A multicenter phase II trial was undertaken to evaluate the efficacy and safety of neoadjuvant capecitabine oxaliplatin combined with bevacizumab patients intermediate-risk adenocarcinoma. Methods. We recruited 46 adenocarcinoma selected by magnetic resonance imaging (MRI) who were candidates (R0) resection located middle third clear mesorectal fascia...
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance common and constitutes main reason failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results largely deceiving. We analysed time to progression, overall survival, mutational status of RAS, BRAF nuclear p-IGF-1R expression by immunohistochemistry, 470 CRC patients. The effect...
This paper reports the preparation of versatile electrochemical biosensing platforms for simple, rapid, and PCR-independent detection most frequent DNA methylation marks (5-methylcytosine, 5-mC, and/or 5-hydroxymethylcytosine, 5-hmC) both at global gene-specific levels. The implemented strategies, relying on smart coupling immuno-magnetic beads (MBs), specific probes amperometric screen-printed carbon electrodes (SPCEs), provided sensitive selective determination target methylated DNAs in...
Abstract Triple-negative breast cancer is a heterogeneous disease characterized by lack of hormonal receptors and HER2 overexpression. It the only subgroup that does not benefit from targeted therapies, its prognosis poor. Several studies have developed specific molecular classifications for triple-negative cancer. However, these subtypes had little impact in clinical setting. Gene expression data information 494 tumors were obtained public databases. First, probabilistic graphical model...